Results 31 to 40 of about 190,081 (230)

Examining the association between oncology drug clinical benefit and the time to public reimbursement

open access: yesCancer Medicine, 2022
Background We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS ...
Sasha Thomson   +7 more
doaj   +1 more source

Planar Four-Bar Motion and Path Generation with Order and Branching Conditions

open access: yesJournal of Advanced Mechanical Design, Systems, and Manufacturing, 2011
This work presents an optimization model for planar four-bar motion and path generation. This model includes the four-bar linkage kinematic model by Suh and Radcliffe(13) as an objective function.
Kevin RUSSELL, John SHEN
doaj   +1 more source

Report on the ASCO 2010 Provider-Payer Initiative Meeting

open access: yes, 2011
The ASCO Provider-Payer Initiative meeting was convened to explore ways in which providers and payers could work together to improve patient care.
Jeffery C. Ward   +4 more
core   +1 more source

Best-of-ASCO Germany 2011 – Aktuelles zu GI-Tumoren, zum NSCLC und zur Supportivtherapie: Chicago meets Frankfurt

open access: yes, 2011
Erstmals fand dieses Jahr in Deutschland die von der Amerikanischen Gesellschaft für Klinische Onkologie (ASCO) lizenzierte Post-ASCO-Nachlese „Best-of-ASCO Germany“ statt. Auf der Veranstaltung, die vom Arbeitskreis Klinischer Studien e.V. (AKS) und der
Birgit Pohlmann
core   +1 more source

ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases

open access: yes, 2010
What does the ASCO provisional clinical opinion on hepatitis B virus mean for practices?
Michael N. Neuss, Robin T. Zon
core   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

open access: yesMolecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani   +7 more
wiley   +1 more source

XI Spotkanie po ASCO [PDF]

open access: yes, 2012
U progu wakacji w dniach 29–30 czerwca 2012 w Gdańskupo raz 11. odbyło się „Spotkanie po ASCO”. Tegorocznaedycja rozpoczęła drugie dziesięciolecie tej znakomitej konferencji,podczas której polscy onkolodzy mogli zapoznaćsię z najnowszymi doniesieniami, i
Sprawozdanie, NOWOTWORY Journal of Oncolo
core  

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China

open access: yesBMC Cancer, 2023
Background Breast cancer patients of American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) Group 2 were all HER2-negative according to the 2018 guideline, not HER2-positive as defined in the 2013 guideline.
Shuling Zhou   +8 more
doaj   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Neues zum Mamma-, Ösophagus- und Prostatakarzinom: ASCO 2010 – aus Berliner Sicht

open access: yes, 2010
Auf einem Pressegespräch wurden einige Themen der mehr als 4500 Vorträge und Poster auf der ASCO-Jahresversammlung 2010 durch ärztliche ASCO-Teilnehmer der Berliner Charité vorgestellt.
Rainer Bubenzer
core   +1 more source

Home - About - Disclaimer - Privacy